whole virion pandemic influenza vaccine

The whole virion pandemic influenza vaccine is an egg-based, whole inactivated virus (WIV) vaccine developed by the National Institute for Public Health and the Environment (RIVM) in collaboration with Intravacc. It is designed to provide broad immunogenicity by including the entire inactivated influenza virion, targeting both humoral and cellular immune responses, primarily against the hemagglutinin surface antigen. This investigational vaccine was evaluated in a Phase I clinical trial in the Netherlands, where it was tested for safety and immunogenicity against pandemic strains such as H5N1. The manufacturing process is designed to be scalable and transferable to vaccine manufacturers in low- and middle-income countries to enhance global pandemic preparedness.

Other names

pandemic WIV vaccinewhole inactivated virus pandemic influenza vaccineH5N1 WIV vaccineH-5N1 WIV vaccineH 5N1 WIV vaccine